Applied DNA Sciences (NASDAQ:APDN) issued an update on its second quarter 2021 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of – for the period. The company issued revenue guidance of $2.50 million-$2.70 million, compared to the consensus revenue estimate of $2.41 million.
A number of analysts recently commented on APDN shares. Zacks Investment Research cut Applied DNA Sciences from a hold rating to a sell rating in a research report on Monday, April 26th. Roth Capital began coverage on shares of Applied DNA Sciences in a research report on Friday, February 12th. They set a buy rating and a $24.00 price objective for the company. Finally, HC Wainwright lowered their target price on Applied DNA Sciences from $14.00 to $13.00 and set a buy rating on the stock in a research report on Wednesday, April 28th.
NASDAQ APDN traded down $0.30 during trading on Tuesday, hitting $5.98. 4,407 shares of the stock traded hands, compared to its average volume of 1,232,235. The company has a market capitalization of $44.69 million, a P/E ratio of -1.82 and a beta of 1.40. Applied DNA Sciences has a 12-month low of $4.95 and a 12-month high of $16.39. The firm has a 50-day simple moving average of $7.36 and a 200-day simple moving average of $8.00. The company has a quick ratio of 2.01, a current ratio of 2.13 and a debt-to-equity ratio of 0.09.
About Applied DNA Sciences
Applied DNA Sciences, Inc develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes applications in the United States, Europe, and Asia.
Recommended Story: What is included in the gross domestic product?
Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with MarketBeat.com's FREE daily email newsletter.